Seismic Therapeutic uses its proprietary IMPACT machine learning platform to design and optimize biologics for immunology. Its preclinical pipeline is led by two programs: S-1117, a pan‑IgG protease sculpting (IgSc) enzyme candidate, and S-4321, a PD‑1 agonist:FcγRIIb‑selective Dual‑cell Bidirectional (DcB) antibody candidate. The company integrates machine learning with protein engineering, structural biology, and translational immunology to parallelize discovery and simultaneously optimize function, immunogenicity, and developability. Proceeds from the recently closed Series B will advance both lead programs through Phase 1 proof-of-mechanism trials, expand the pipeline in the IgSc and DcB areas, and further develop the IMPACT platform with additional methods. Seismic has advanced two programs into IND‑enabling studies since its Series A and is backed by a broad syndicate of life‑science investors. The company is located in the Boston/Cambridge biotechnology hub. Seismic Therapeutic develops biologic therapeutics for autoimmune diseases by fully integrating machine learning with structural biology, protein engineering and translational immunology via its IMPACT™ platform. The IMPACT platform parallelizes interdisciplinary components of drug discovery to design and analyze vast numbers of proteins in parallel, optimizing both function and developability. The company has an emerging pipeline of novel biologics targeting dysregulated adaptive immunity, including two lead programs—one for Ig-mediated autoimmunity and one for cell-mediated autoimmunity. Seismic launched with a $101 million Series A to fund advancement toward the clinic of those lead programs and to continue building its proprietary platform. The team includes drug developers, machine learning innovators, and academic founders with expertise in immunology, structural biology and protein engineering. Seismic is based in the Boston/Watertown, Mass. biotechnology hub.

Total raised

$222M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2023